Category: General News
Search News
BCI researcher receives new Pancreatic Cancer UK Fellowship
20th July 2022
Congratulations to Dr Audrey Lumeau, Postdoctoral Researcher at Barts Cancer Institute, Queen Mary University of London, who has received a Career Foundation Fellowship from the charity Pancreatic Cancer UK to investigate chromosomal instability in pancreatic cancer and its role in therapy resistance.
Read more
Science and art collide at this year’s Royal Academy’s Summer Exhibition
21st June 2022
An artwork by Professor Tyson V. Sharp from Barts Cancer Institute at Queen Mary University of London has been selected for display in Room VIII at the Royal Academy of Art’s prestigious Summer Exhibition.
Read more
BCI researcher joins global Cancer Grand Challenges team
16th June 2022
Dr Benjamin Werner from Barts Cancer Institute at Queen Mary University of London is part of a world-class team of researchers that has been selected to receive a £20m Cancer Grand Challenges award to tackle the challenge of extrachromosomal DNA, a major driver of tumour evolution present in around a third of cancers.
Read more
BCI researcher receives prestigious MRC grant to investigate how HPV infection develops into cancer
27th May 2022
Dr Sarah McClelland from BCI is part of a collaborative project that has secured £1.2 million in funding from the Medical Research Council to investigate the mechanisms leading to cancer development in cells infected with human papillomavirus.
Read more
In conversation with Professor Marco Gerlinger
20th May 2022
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
Read more
£3.1 million for PROTECT trial
6th May 2022
Yorkshire Cancer Research has announced a £3.1 million grant for research led by Ranjit Manchanda to investigate the risks, benefits, and feasibility of introducing population-based genetic testing for ‘all’ women to find out if they are at high risk of cancer. Thousands of women living in Yorkshire and other parts of the UK will be offered tests as part of the PROTECT (Population based germline testing for early detection and cancer prevention) clinical trial.
Read more